AtriCure Analysts Lift Targets After Q3 Beat

ATRC enters November with momentum behind it: a strong earnings print just delivered, three analysts immediately raising price targets to $70, and short interest sitting at a meaningful 9.8% of free float that has been building quietly all month.

The analyst response to the Q3 results was swift and unanimous on direction. Piper Sandler, Needham, and BTIG all raised their targets to $70 on November 4, the day after the print. Piper Sandler moved from $60 to $70 while reiterating Overweight. Needham lifted from $64 to $70. BTIG raised from $63 to $70. That convergence on the same number from three separate firms is notable. Citizens had already pushed its target to $68 two weeks prior. The lone dissenter in recent months is Freedom Capital Markets, which downgraded to Hold in early October while raising its target to $57. With the stock at $60.41, the consensus target of $57.56 looks stale relative to the fresh post-earnings cluster, and the new $70 prints sit roughly 16% above the current price.

The bull case centres on underpenetrated markets and an accelerating product pipeline. Pain Management grew 27% in the first half of 2026. Open Ablation and Appendage Management added 13% and 10% respectively. Management is pointing to low-teens revenue growth with adjusted EBITDA of $100 million in FY27 and $120 million in FY28. The new STS quality measure, together with pipeline catalysts BoxX-NoAF and LeAAPS, could deepen utilisation across a roughly $470 million domestic open-ablation market. Bears counter that the stock has roughly doubled since June and already reflects much of that optimism. At close to 30x EV/EBITDA and a trailing P/E above 147, valuation leaves little room for execution slippage, and physician adoption remains uneven. The EPS surprise factor score ranks in the 98th percentile, a strong track record, though the 12-month forward EPS growth score is a more modest 25th percentile, meaning the Street does not expect that beat cadence to accelerate from here.

Positioning tells a more cautious short-side story than the analyst enthusiasm might suggest. Short interest at 9.8% of free float is meaningful, and it has climbed roughly 12% over the past month, with the bulk of that build arriving in the week of October 26. That said, the lending market is not tight. Availability has expanded sharply, with roughly 570% of short interest currently available to borrow, well clear of even the 52-week low availability of 248%. Cost to borrow has ticked up 45% over the past week but remains low in absolute terms at 0.49%. The short score of 54.9 is neutral and has been drifting sideways. This is a measured short position, not a crowded or distressed one. Options positioning is also relaxed: the put/call ratio of 0.053 is well below its 20-day average of 0.092, and the negative z-score confirms calls are dominating, consistent with the bullish analyst tone post-results.

One institutional development worth noting is BlackRock's disclosed stake, which has grown from 7.8% to 15.4% as of its October 5 filing, making it by far the largest single holder. That is a substantial position increase for the index giant, though as with all 13G disclosures, the figure reflects the last filing date and may have shifted since. The stock was added to the S&P SmallCap 600 in September, an event that mechanically drew index-tracker buying. BlackRock's move from 7.8% to 15.4% across two filings may partly reflect that rebalancing flow rather than active conviction, though the timing and scale are worth monitoring as future filings emerge.

Insider activity over the 90 days to late September was net negative at around $3.3 million in open-market sales, but the picture is mixed in character. The CTO's sales were conducted under a 10b5-1 pre-arranged plan, which reduces their signalling value. The Chief Legal Officer and two directors sold in discretionary transactions, though at prices of $38 to $55, well below the current $60 level. No open-market purchases were filed in the period.

The next earnings event is not until February 12, 2027, leaving roughly 100 days for the post-Q3 narrative to develop. Retail attention, as measured by Wikipedia page views, produced an unusually high z-score of 7.4 around October 19, suggesting the stock drew significant interest around the time of the earnings announcement. The key question for the coming weeks is whether the $70 analyst target cluster draws new institutional buyers at current levels, or whether the month-long build in short interest reflects a cohort that sees the valuation as the ceiling rather than the floor.